14 results about "Cardiogenic shock" patented technology

1. Name of the product in this design: Percutaneous ventricular assist device. 2. Purpose of this design: for use in medical and health care, for emergency support in cases of acute myocardial infarction, cardiogenic shock, high-risk PCI, etc. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

A subject can be treated for cardiogenic shock and / or sepsis, or their symptoms using platelet-derived extracellular vesicles (PEVs) or mitlets that include PEVS. The PEVs include mitochondria. The PEVs can be collected by obtaining blood from one or more donors, adding an anticoagulant and a buffer to the blood to form a mix, separating the mix into supernatant and platelet rich plasma (PRP), collecting the PRP and stimulating the collected PRP, thereby expelling extracellular vesicles from platelets in the PRP, and collecting the extracellular vesicles as the PEVs. PEVs can also be isolated from source cells grown in a bioreactor and suspended in a buffer to preserve the PEVs.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

1. The name of the design product: main trolley. 2. The use of the design product: for clinical first aid of myocardial infarction, cardiogenic shock and other serious coronary heart disease. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective drawing.

A method and system for predicting whether a patient is likely to develop post-cardiotomy cardiogenic shock (PCCS) are described. The method includes receiving medical information about a patient, extracting one or more features from the received medical information, providing the one or more features as input to a trained classification model configured to output a risk assessment that the patient is likely to develop PCCS, and outputting an indication of the risk assessment.

The present invention relates to a protein myeloid-derived growth factor (MYDGF) or a nucleic acid encoding said protein for use in the treatment and / or prevention of cardiac shock. The invention also relates to a vector comprising said nucleic acid, a host cell expressing said nucleic acid, and a pharmaceutical composition comprising said protein, nucleic acid, vector or host cell for use in the treatment and / or prevention of cardiac shock, as well as a method for the treatment and / or prevention of cardiac shock. The invention also relates to a method for preparing a cardiac shock animal model, and to the animals obtained by said method.

A method (100) for training a hemodynamic instability cause classification model to classify a patient's determined likelihood of future hemodynamic instability as caused by one or more of cardiogenic shock, septic shock, and hypovolemic shock, the method comprising: (i) receiving (120) a preliminary cause classification model training dataset; (ii) analyzing (130) the received dataset to classify each patient as likely to be hemodynamically unstable; (iii) analyzing (140) the received patient information by an outlier detection model to determine whether that patient's hemodynamic instability is likely to be cardiogenic shock, septic shock, hypovolemic shock, or an outlier; (iv) generating (150) a final cause classification model training dataset by removing each of the patients determined as being an outlier; and (v) training (160) the hemodynamic instability cause classification model to classify a cause of the patient's determined likelihood of future hemodynamic instability.

1. The name of the design product: IABP host trolley. 2. The use of the design product: for clinical first aid of severe coronary heart disease such as cardiac insufficiency, myocardial infarction, cardiogenic shock, etc. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 2. 5. The bottom view of the design product is not easy to see or not visible during use, and the bottom view is omitted.

To provide systems and methods for treating a patient in cardiogenic shock.SOLUTION: An intravascular heart pump system is inserted into the vasculature of the patient. The heart pump system has a cannula, a pump outlet, a pump inlet, and a rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. Multiple features are extracted from the data. A probability of survival of the patient is determined based on the multiple features and using a prediction model. The heart pump system is operated to treat the patient.SELECTED DRAWING: Figure 1

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

The invention relates to the technical field of heart rate detection, in particular to a special heart rate detection method and device for a railway in a severe environment, and the method comprises the steps: collecting a heart impact signal in real time, and carrying out the signal preprocessing of the heart impact signal, and obtaining the preprocessed heart impact signal; inputting the preprocessed ballistocardiogram signal into the trained TimeGAN network model to obtain a final ballistocardiogram signal; inputting the final ballistocardiogram signal into the body movement detection network model, and classifying the normal detection segments and the body movement detection segments to obtain the normal detection segments; the body movement detection network model is a combined network model combining a full convolutional network and a bidirectional long short-term memory network; the normal detection segments are input into the cardiac interval detection model, a J-peak timestamp sequence is obtained, a final heart rate result is obtained according to the J-peak timestamp sequence, and when the heart rate result conforms to a preset rule, an alarm is given. The technical problem that in the prior art, heart rate measurement is complex and inaccurate is solved.

Compositions for intravenous infusion of istaroxime or derivatives thereof in human patients suffering from AHF with acute myocardial ischemia and / or an acute myocardial infarction are disclosed. The patient may optionally be in early cardiogenic or cardiogenic shock. Likewise, methods of administering istaroxime or derivatives thereof to individuals exhibiting symptoms of, or having been diagnosed with AHF with acute myocardial ischemia and / or an acute myocardial infarction. In particular-, disclosed herein is a method of reducing the risk of or preventing acute myocardial arrhythmias in an individual being treated for AHF with acute myocardial ischemia and / or acute myocardial infarction by administering to the individual a dosage regimen of istaroxime or CVie 216 by intravenous infusion.

Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.